MedPath

Comparison of Four and Eight Hours Dialysis Sessions in Thrice Weekly Hemodialysis

Phase 4
Completed
Conditions
End-Stage Renal Disease
Hemodialysis
Interventions
Procedure: 4-hour thrice weekly in center hemodialysis
Procedure: 8-hour thrice weekly in center hemodialysis
Registration Number
NCT00413803
Lead Sponsor
Ege University
Brief Summary

The investigators hypothesize that an increase in the duration of dialysis session in thrice weekly center hemodialysis may provide better outcome, less morbidity, higher quality of life, lesser requirement of medications, and lower total cost.

Detailed Description

The proposed prospective and controlled clinical trial aims to compare 4-hour and 8-hour dialysis sessions in thrice weekly center HD regarding mortality, hospitalization rate, several clinical and laboratory parameters, and total cost. Four hundred and ten HD patients will be taken into the study. The study will last for 12 months. The patients will be placed in two groups:

1. Four-hour dialysis session, blood flow rate 300-400 ml/min

2. Eight-hours dialysis session, blood flow rate 200-250 ml/min

Sample size is estimated with following hypotheses: twelve months duration of follow-up; twelve months survival of the control group 85%; a bilateral alpha risk equal to 5%; an expectation that 12-months survival to be 95% by 8-hours dialysis; a 85% power to detect the decrease in annual mortality by 8-hours dialysis comparing to 4-hours dialysis; a 10% of dropout rate. The required sample is total 410 patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
410
Inclusion Criteria
  • Older than 18-years
  • On maintenance bicarbonate HD scheduled thrice weekly 12 hours/week; achieved mean single pool Kt/V above 1.2
  • Willingness to participate in the study with a written informed consent
Exclusion Criteria
  • To be scheduled for living donor renal transplantation
  • To have serious life-limiting co-morbid situations, namely active malignancy, active infection, end-stage cardiac, pulmonary, or hepatic disease
  • Pregnancy or lactating
  • Current requirement for HD more than three times per week due to medical comorbidity
  • GFR greater than 10 ml/min/1.73 m2 as measured by the average of urea and creatinine clearances obtained from a urine collection of at least 24 hours
  • Use of temporary catheter
  • Current use of investigational drugs or participation in an interventional clinical trial that contradicts or interferes with the therapies or measured outcomes in this trial
  • Mental incompetence

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
14-hour thrice weekly in center hemodialysisFour-hour dialysis session, blood flow rate 300-400 ml/min
28-hour thrice weekly in center hemodialysisEight-hours dialysis session, blood flow rate 200-250 ml/min
Primary Outcome Measures
NameTimeMethod
total mortalityone year
Secondary Outcome Measures
NameTimeMethod
cardiovascular mortalityone year
changes in health-related quality of life, depression burden, cognitive functionone year
required medicationsone year
total costone year
changes in blood pressure, left ventricular geometry, coronary artery calcification, arterial stiffness,upper mid-arm circumference,hematocrit and related rHu-EPO doses, the levels of phosphorus, albumin, lipid parameters, hsCRP, and β-2 microglobulinone year
hospitalization rateone year
Vascular access patencyone year
post-dialysis body weight and total body waterone year
arrythmia episodes determined by Holter-ECGone year

Trial Locations

Locations (2)

FMC Turkey Clinics

🇹🇷

Adana, Turkey

Ege University School of Medicine Nephrology Department

🇹🇷

Izmir, Turkey

© Copyright 2025. All Rights Reserved by MedPath